PATENT CLAIM ANALYSIS

Application Number: 16160432
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "167000"]

Abstract:
A pharmaceutical composition and method reduces statin-related side effects, including myalgia, myositis, myopathy, and myonecrosis. The composition comprises at least one HMG-CoA reductase inhibitor (statin) and vitamin D. The composition may comprise one or more excipient. The pharmaceutical composition is adapted to decrease side effects of said HMG-CoA reductase inhibitors. The excipient may comprise one or more excipient delivery agent providing immediate release, sustained release, extended release and/or combination thereof of said HMG-CoA and/or vitamin D. The amount of the vitamin D may be fixed or variable. A method of treating hyperlipidemia is provided comprising an orally administered pharmaceutical composition having at least one HMG-CoA reductase inhibitor and vitamin D. Preferably, the pharmaceutical composition is administered once per day, via oral, nonoral, transdermal and/or injection drug delivery.

Claim (Index 7):
The pharmaceutical composition as recited by  claim 1 , wherein said amount of said vitamin D is a variable amount delivered by one or more of immediate release, sustained release and extended release.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 97.0
- Lexical Diversity: 1.92
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12143217', '10983836', '14853374', '10624659', '15211152']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7900506093529822
- 35 USC 102 Novelty (BERT): 0.5288115085716055
- Combined Prediction Score: 0.7639266992748446
- Mean Citation Score: 269.66564
- Max Citation Score: 323.53235
- Similarity Product: 181.74057409756185

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test